Cyclerion Therapeutics, Inc. (CYCN)
NASDAQ: CYCN · Real-Time Price · USD
2.540
+0.040 (1.60%)
At close: Apr 1, 2025, 4:00 PM
2.555
+0.015 (0.59%)
After-hours: Apr 1, 2025, 4:02 PM EDT
Cyclerion Therapeutics Revenue
In the year 2024, Cyclerion Therapeutics had annual revenue of $2.00M. Cyclerion Therapeutics had revenue of $1.81M in the quarter ending December 31, 2024.
Revenue (ttm)
$2.00M
Revenue Growth
n/a
P/S Ratio
3.15
Revenue / Employee
$2,000,000
Employees
1
Market Cap
6.47M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
CYCN News
- 3 months ago - Cyclerion's sGC Stimulator Portfolio Generates Revenues to Enable Company Growth - GlobeNewsWire
- 8 months ago - Regina Graul, Ph.D., Promoted to Chief Executive Officer - GlobeNewsWire
- 1 year ago - Cyclerion Appoints Regina Graul, Ph.D., as President - GlobeNewsWire
- 1 year ago - Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator - GlobeNewsWire
- 1 year ago - Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets - GlobeNewsWire
- 1 year ago - Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewsWire
- 2 years ago - Cyclerion Announces Reverse Stock Split - GlobeNewsWire
- 2 years ago - Cyclerion Announces Definitive Agreement for Zagociguat and CY3018 - GlobeNewsWire